Doctors could have a new treatment option for protecting newborn infants from respiratory syncytial virus if the Food and Drug Administration approves Merck & Co.’s drug clesrovimab by next summer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,